

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over

Information for the public

Published: 12 February 2025

www.nice.org.uk

Selpercatinib (Retsevmo) is available on the NHS. It is a possible treatment for:

- RET-mutant medullary thyroid cancer that has spread to other parts of the body (advanced)
- RET fusion-positive advanced thyroid cancer, when radioactive active iodine has not worked if it is an appropriate treatment.

It is for people 12 years and over. It is only available if the cancer has not been treated with a targeted cancer drug.

If you are not eligible for selpercatinib but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on thyroid cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [AMEND](#), info@amend.org.uk
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6843-5